Microbiology and Biotechnology Letters (한국미생물·생명공학회지)

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

The Role of Complement in the Immunologic Microenvironment of Tumor Cells: Potential Therapeutic Targets

  • Jo, Kyeong Beom (Department of Bioscience Education, King's College London) ;
  • Snape, Alison (Department of Bioscience Education, King's College London)
  • Received : 2016.08.22
  • Accepted : 2016.11.13
  • Published : 2016.12.28
Download PDF
⟨ Previous Next ⟩

Abstract

The complement system comprises a set of essential molecules that bridge the innate and adaptive immune responses. Research has focused on how the complement system's destructive mechanism could potentially be harnessed for cancer treatment. However, cancer subverts the complement system to avoid immunosurveillance. In addition, a complement-triggered biological mechanism that contributes to cancer growth has been identified. Thus, drugs should be designed to homeostatically maintain a normal concentration of complement. This review explores three types of complement-related anti-cancer drugs: therapeutic antibodies, complement inhibitory drugs, and anti-complement regulatory drugs.

Keywords

References

  1. Austin EB, Robins RA, Durrant LG, Price MR, Baldwin RW. 1989. Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36. J. Immunology 67: 525-530.
  2. Bu X, Zheng Z, Wang C, Yu Y. 2007. Significance of C4d deposition in the follicular lymphoma and MALT lymphoma and their relationship with follicular dendritic cells. Pathol. Res. Pract. 203: 163-167. https://doi.org/10.1016/j.prp.2006.11.004
  3. Bureeva S, Andia-Pravdivy J, Kaplun A. 2005. Drug design using the example of the complement system inhibitors' development. Drug Discov. Today 10: 1535-1542. https://doi.org/10.1016/S1359-6446(05)03592-0
  4. Cheung NK, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, Medof ME. 1988. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J. Clin. Invest. 81: 1122-1128. https://doi.org/10.1172/JCI113426
  5. Cimino-Mathews A, Foote JB, Emens LA. 2015. Immune targeting in breast cancer. Oncology 29: 375-385.
  6. Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD. et al. 2012. Anaphylatoxin c5a creates a favorable microenvironment for lung cancer progression. J. Immunol. 189: 4674-4683. https://doi.org/10.4049/jimmunol.1201654
  7. Davis AE, Lu F, Mejia P. 2010. C1 inhibitor, a multi-functional serine protease inhibitor. Thromb. Haemost. 104: 886-893. https://doi.org/10.1160/TH10-01-0073
  8. Donin D, Jurianz K, Ziporen L, Schultz S. Kirschfink M, Fishelson Z. 2003. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin. ExpImmunol. 131: 254-263.
  9. Dougan M, Dranoff G. 2009. Immune therapy for cancer. Annual Rev. Immunol. 27: 83-117. https://doi.org/10.1146/annurev.immunol.021908.132544
  10. Durrant LG, Chapman MA, Buckley DJ, Spendlove I, Robins RA, Armitage NC. 2003. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer. Immunol. Immunother. 52: 638-642. https://doi.org/10.1007/s00262-003-0402-y
  11. Ferlay J, SoerjomataramI, Ervik M, Dikshit R, Eser S, Mathers C, et al. 2013. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Available from http://globocan.iarc.fr. Accessed December 2015.
  12. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. 2003. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol. 40: 109-123. https://doi.org/10.1016/S0161-5890(03)00112-3
  13. Gasque P, Thomas A, Fontaine M, Morgan BP. 1996. Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. J. Neuroimmunol. 66: 29-40. https://doi.org/10.1016/0165-5728(96)00015-X
  14. Gminski J, Mykala-Ciesla J, Machalski M, Drozdz M, Najda J. 1992. Immunoglobulins and complement components levels in patients with lung cancer. Rom. J. Intern. Med. 30: 39-44.
  15. Gunn L, Ding C, Liu M, Ma Y, Qi C, Cai Y. et al. 2012. Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J. Immunol. 189: 2985-2994. https://doi.org/10.4049/jimmunol.1200846
  16. Guo RF, Ward PA. 2005. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23: 821-852. https://doi.org/10.1146/annurev.immunol.23.021704.115835
  17. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. 2012. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev. 38: 904-910. https://doi.org/10.1016/j.ctrv.2012.04.007
  18. Janssen BJ, Halff EF, Lambris JD, Gros P. 2007. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J. Biol. Chem. 282: 29241-29247. https://doi.org/10.1074/jbc.M704587200
  19. Kempshall E, Thebault S, Morgan BP, Harris CL, Gallimore A. 2012. Complement-induced protection: an explanation for the limitations of cell-based tumour immunotherapies. Immunol. Cell Biol. 90: 869-871. https://doi.org/10.1038/icb.2012.30
  20. Kolev M, Towner L, Donev R. 2011. Complement in cancer and cancer immunotherapy. Arch. Immunol. Ther. Exp. (Warsz). 59: 407-419. https://doi.org/10.1007/s00005-011-0146-x
  21. Kraus S, Fishelson Z. 2000. Cell densensitization by sublytic C5Bb-9 complexes and calcium ionophores depends on activatin of protein kinase C. Eur. J. Immunol. 30: 1272-1280. https://doi.org/10.1002/(SICI)1521-4141(200005)30:5<1272::AID-IMMU1272>3.0.CO;2-9
  22. Kraus S, Seger R, Fishelson Z. 2001. Involvement of the ERK mitogen-activated protein kinase in cell resistance to complement-mediated lysis. Clin. ExpImmunol. 123: 366-374.
  23. Kraut EH, Sagone AL Jr. 1981. Alternative pathway of complement in multiple myeloma. Am. J. Hematol. 11: 335-345. https://doi.org/10.1002/ajh.2830110402
  24. Kuraya M, Yefenof E, Klein G, Klein E. 1992. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis. Eur. J. Immunol., 22: 1871-1876. https://doi.org/10.1002/eji.1830220729
  25. Lucas SD, Karlsson-Parra A, Nilsson B, Grimelius L, Akerstrom G, Rastad J. et al.1996. Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Hum. Pathol. 27: 1329-1335. https://doi.org/10.1016/S0046-8177(96)90346-9
  26. Maness PF, Orengo A. 1977. Serum complement levels in patients with digestive tract carcinomas and other neoplastic diseases. Oncology 34: 87-89. https://doi.org/10.1159/000225191
  27. Markiewski MM, Lambris JD. 2007. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am. J. Pathol. 171: 715-727. https://doi.org/10.2353/ajpath.2007.070166
  28. Markiewski MM, Lambris JD. 2009. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol. 30: 286-292. https://doi.org/10.1016/j.it.2009.04.002
  29. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C. et al. 2008. Modulation of the antitumor immune response by complement. Nat. Immunol. 9: 1225-1235. https://doi.org/10.1038/ni.1655
  30. McConnell I, Klein G, Lint TF, Lachmann PJ. 1978. Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells. Eur. J. Immunol. 8: 453-458. https://doi.org/10.1002/eji.1830080702
  31. Morgan BP, Harris CL. 2015. Complement, a target for therapy in inflammatory and degenerative disease. Nat. Rev. Drug Discov. 14: 857-877. https://doi.org/10.1038/nrd4657
  32. Niculescu F, Badea T, Rus H. 1999. Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. Atherosclerosis. 142: 47-56. https://doi.org/10.1016/S0021-9150(98)00185-3
  33. Niculescu F, Rus H, Van Biesen T, Shin ML. 1997. Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent. J. Immunol. 158: 4405-4412.
  34. Niculescu F, Rus HG, Retegan M, Vlaicu R. 1992. Persistent complement activation on tumor cells in breast cancer. Am. J. Pathol. 140: 1039-1043.
  35. Nishioka K, Kawamura K, Hirayama T, Kawashima T, Shimada K. 1976. The complement system in tumor immunity: significance of elevated levels of complement in tumor bearing hosts. Ann. N Y Acad. Sci. 276: 303-315. https://doi.org/10.1111/j.1749-6632.1976.tb41656.x
  36. Nunez-Cruz S, Gimotty PA, Guerra MW, Connolly, DC, Wu Y-Q, DeAngelis RA. 2012. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 14: 994-1004. https://doi.org/10.1593/neo.121262
  37. Pio R, Ajona D, Lambris JD. 2013. Complement inhibition: promising concept for cancer treatment. Semin. Immunol. 25: 54-64. https://doi.org/10.1016/j.smim.2013.04.001
  38. Ricklin D, Hajishengallis G, Yang K, Lambris JD. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797. https://doi.org/10.1038/ni.1923
  39. Ricklin D, Lambris JD. 2007. Complement-targeted therapeutics. Nat. Biotechnol. 25: 1265-1275. https://doi.org/10.1038/nbt1342
  40. Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT. 2010. Cancer and the complement cascade. Molecul. Cancer Res. 8: 1453-1465. https://doi.org/10.1158/1541-7786.MCR-10-0225
  41. Sahu A, Lambris JD. 2000. Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology 49: 133-148. https://doi.org/10.1016/S0162-3109(00)80299-4
  42. Sahu A, Morikis D, Lambris JD. 2003. Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. MolImmunol. 39: 557-566.
  43. Spendlove L, Li L, Potter V, Christiansen D, Loveland BE, Durrant LG. 2000. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions. Eur. J. Immunol. 30: 2944-2953. https://doi.org/10.1002/1521-4141(200010)30:10<2944::AID-IMMU2944>3.0.CO;2-U
  44. Spiller OB, Criado-Garcia O, Rodriguez De Cordoba S, Morgan BP. 2000. Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin. ExpImmunol. 121: 234-241.
  45. Swann JB, Smyth MJ. 2007. Immune surveillance of tumour. J. Clin. Invest. 117: 1137-1146. https://doi.org/10.1172/JCI31405
  46. Szebeni J. 2004. The complement system: Novel Roles in Health and Disease. Boston: Kluwer Academic Publishers. 4: 265-304.
  47. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. 2006. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177: 362-377. https://doi.org/10.4049/jimmunol.177.1.362
  48. Tegla CA, Cudrici C, Patel S, Trippe R, Rus V, Niculescu F. et al. 2011. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol. Res. 51: 45-60. https://doi.org/10.1007/s12026-011-8239-5
  49. Vagas-Madrazo E, Lara-Ochoa F, Almagro JC. 1995. Canonical structure repertoire of the antigen-binding site of immunoglobulins suggests strong geometrical restrictions associated to the mechanism of immune recognition. J. Mol. Biol.254: 497-504. https://doi.org/10.1006/jmbi.1995.0633
  50. Woodruff TM, Nandakumar KS, Tedesco F. 2011. Inhibiting the C5-C5a receptor axis. MolImmunol. 48: 1631-1642.
  51. Ytting H, Jensenius JC, Christensen J, Thiel S, Nielsen HJ. 2004. Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer. Scand J. Gastroenterol. 39: 674-679. https://doi.org/10.1080/00365520410005603
  52. Zipfel PF, Skerka C. 2009. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9: 729-740. https://doi.org/10.1038/nri2620